Pfizer to expand venture investing with $600 million commitment to Pfizer Ventures
- Details
- Category: Pfizer
Pfizer Inc. (NYSE:PFE) today announced it plans to invest $600 million in biotechnology and other emerging growth companies through Pfizer Ventures, the company’s venture investment vehicle. In addition to increased funding, Pfizer will extend its leadership as a venture capital investor with an expanded team that leverages expertise across venture capital investing, business development, drug discovery and clinical development.
Novartis receives positive CHMP opinion for Aimovig® (erenumab) for the prevention of migraine
- Details
- Category: Novartis
Novartis announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval for Aimovig® (erenumab) for the prevention of migraine in adults who have at least four migraine days per month. The World Health Organization (WHO) has listed migraine as one of the top ten causes of years lived with disability worldwide[1].
The Pfizer Foundation announces $5 million in grants to support women and families
- Details
- Category: Pfizer
The Pfizer Foundation announced a new $5 million grant commitment to initiatives in low- and middle-income countries that provide family planning access and education for women and men at the same time children are routinely vaccinated. These new grants build on The Pfizer Foundation's existing grant program by providing a second round of funding to international nongovernmental organizations (INGOs) in five African countries where different barriers exist for women to access family planning services, bringing the total program funding to $11.7 million to date.
Amgen Foundation and Harvard team up to offer free online science education platform
- Details
- Category: Amgen
The Amgen Foundation and Harvard University today announced plans to launch a free online science education platform uniquely designed to level the playing field for aspiring scientists. The LabXchange platform, which will launch with a focus in biology, will offer digital instruction and virtual lab experiences to high school and college students, enabling them to gain meaningful exposure to the scientific process.
Patient-reported outcomes tool revealed significant improvement in symptom frequency and quality of life domains with Entresto®
- Details
- Category: Novartis
Novartis announced today new real world evidence from the CHAMP-HF registry comparing Entresto® (sacubitril/valsartan) patients to patients not taking Entresto.[1] This pre-specified analysis of an interim data cut from the CHAMP-HF registry showed that chronic heart failure (HF) patients with reduced ejection fraction (HFrEF) taking Entresto reported early, statistically significant improvement in health status, as measured by the KCCQ-12 overall summary score (KCCQ-OS).
AstraZeneca heads to 2018 ASCO Annual Meeting with its diversified oncology portfolio and next-generation pipeline
- Details
- Category: AstraZeneca
AstraZeneca and MedImmune, its global biologics research and development arm, head to the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, US, 1-5 June 2018, with an expanded portfolio in Oncology. Having achieved 16 regulatory approvals across major markets (US, EU, Japan and China), AstraZeneca will be sharing its R&D momentum at ASCO with seven "Best of ASCO" presentations and 14 oral presentations from a total of 91 accepted abstracts.
Spiolto® Respimat® enables greater physical activity in people living with Chronic Obstructive Pulmonary Disease
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim announced data which add to the growing body of evidence that show Spiolto® (tiotropium/olodaterol) Respimat® enables greater physical activity in patients living with COPD. VESUTO® and OTIVATO® data were presented during the American Thoracic Society meeting (ATS) and PHYSACTO® data was recently published in the American Journal of Respiratory and Critical Care Medicine.
More Pharma News ...
- Pfizer begins a Phase 1/2 study to evaluate respiratory syncytial virus (RSV) vaccine
- Novartis data at ASCO and EHA reinforce company's commitment to reimagining cancer
- Novo Nordisk increases commitment to stem cell-based therapies
- Sanofi and Ablynx announce the successful results of the initial tender offer period
- AstraZeneca provides update on GALATHEA Phase III trial for Fasenra in chronic obstructive pulmonary disease
- Alcon Cares Project 100 commits to reducing cataract blindness globally
- FDA grants priority review to Roche's cancer immunotherapy TECENTRIQ (atezolizumab) for initial treatment of people with a specific type of metastatic lung cancer